Analysis of the efficacy, role and clinical effects of guselkumab (Tenoya)

Guselkumab (Guselkumab) is a fully humanized monoclonal antibody that mainly targets interleukin-23 ( IL-23)p19 subunit, by specifically inhibiting the IL-23 signaling pathway, thereby reducing the release of inflammatory factors and the activation of immune cells. IL-23Plays a key role in psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Excessive activation can lead to the formation of skin scales and joint inflammation. The targeting effect of guselkumab enables it to precisely regulate the immune response and fundamentally intervene in the disease process.

Guselkumab has shown significant efficacy in the treatment of psoriasis. Clinical studies have shown that most patients with moderate to severe plaque psoriasis who receive guselkumab treatment have significant improvement in skin lesion area and symptoms within 12 weeks, and some patients can reach PASI 90 or higher, that is, the skin affected area is reduced by more than 90%. Compared with traditional systemic treatments such as methotrexate or cyclosporine, guselkumab has a more sustained efficacy and a relatively low recurrence rate, providing a new option for long-term management.

Guselkumab also showed good relief of joint symptoms in patients with psoriatic arthritis.通过抑制IL-23/Th17轴，可降低关节炎症和疼痛，改善关节功能和生活质量。 Multiple clinical trials have shown that guselkumab combined with standard treatment regimens can significantly improve the joint symptom relief rate and is safe. Most adverse reactions are mild to moderate, such as upper respiratory tract infection, injection site reaction, etc., and there are few serious adverse events.

Overall, guselkumab has become an important treatment option for moderate to severe plaque psoriasis and psoriatic arthritis due to its precise targeting mechanism and significant clinical efficacy. Its advantages include high efficiency, sustainability, strong targeting, and relatively good safety. In clinical use, doctors will develop an individualized plan based on the severity of the patient's condition, previous treatment experience, and comorbid symptoms to achieve maximum efficacy, reduce potential risks, and improve the patient's long-term quality of life.

Reference materials:https://www.nlm.nih.gov/